Coverage
-
February 03, 2016
One of four whistleblower complaints accusing Biogen Inc. of violating the False Claims Act by paying millions of dollars in kickbacks to doctors as incentives and rewards for prescribing the company's multiple sclerosis drugs to Medicare patients was voluntarily dismissed from Massachusetts federal court Wednesday.
1 other articles on this case.
View all »